
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5302446/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ALK-positiveÂhistiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood, 2022, 139, 256-280.	1.4	60
2	Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. Cancers, 2022, 14, 1606.	3.7	7
3	Cutaneous histiocytoses in children. Histopathology, 2022, 80, 196-215.	2.9	14
4	Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab. Cancer Immunology, Immunotherapy, 2022, 71, 2791-2799.	4.2	3
5	Granulomatous splenic mass with necrosis revealing an EBV-positive inflammatory follicular dendritic cell sarcoma. Journal of Surgical Case Reports, 2022, 2022, rjac034.	0.4	1
6	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	7.2	1,211
7	Malignant Histiocytosis With PD-L1 Expression—Dramatic Response to Nivolumab. Mayo Clinic Proceedings, 2022, 97, 1401-1403.	3.0	3
8	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	1.4	30
9	Second primary cutaneous melanoma in patients with advanced melanoma treated with antiâ€programmedâ€deathâ€receptorâ€1 monoclonal antibodies. British Journal of Dermatology, 2021, 184, 746-748.	1.5	1
10	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Digestive and Liver Disease, 2021, 53, 318-323.	0.9	14
11	Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Cancers, 2021, 13, 1234.	3.7	10
12	Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 1107.	3.7	16
13	Shwachmanâ€Ðiamond syndrome and solid tumors: Three new patients from the French Registry for Severe Chronic Neutropenia and literature review. Pediatric Blood and Cancer, 2021, 68, e29071.	1.5	4
14	Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. European Journal of Cancer, 2021, 148, 171-180.	2.8	7
15	Peritoneal or mesenteric tumours revealing histiocytosis. BMJ Open Gastroenterology, 2021, 8, e000622.	2.7	3
16	Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro-Oncology, 2021, 23, 1433-1446.	1.2	33
17	Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review Frontiers in Medicine, 2021, 8, 678456.	2.6	3
18	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nature Medicine, 2021, 27, 1646-1654.	30.7	65

#	Article	IF	CITATIONS
19	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research, 2021, 27, 4768-4780.	7.0	25
20	<scp><i>CARMNâ€NOTCH2</i></scp> fusion transcript drives high <scp>NOTCH2</scp> expression in glomus tumors of the upper digestive tract. Genes Chromosomes and Cancer, 2021, 60, 723-732.	2.8	11
21	A circulating subset of <i>BRAF</i> <sup>V600E</sup> â€positive cells in infants with highâ€risk Langerhans cell histiocytosis treated with BRAF inhibitors. British Journal of Haematology, 2021, 194, 745-749.	2.5	5
22	Histiocytosis. Lancet, The, 2021, 398, 157-170.	13.7	58
23	IgG4-related disease and Rosai-Dorfman-Destombes disease – Authors' reply. Lancet, The, 2021, 398, 1214-1215.	13.7	0
24	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Digestive and Liver Disease, 2021, 53, 1254-1259.	0.9	5
25	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 97.	3.7	6
26	Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood Cells, Molecules, and Diseases, 2021, 92, 102623.	1.4	0
27	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). European Journal of Cancer, 2021, 159, 24-33.	2.8	24
28	Pediatric Erdheim-Chester Disease in the Molecular Era: A Multicenter Case Series. Blood, 2021, 138, 4194-4194.	1.4	1
29	Case Report: Evolution of a Severe Vascular Refractory Form of ECD Requiring Liver Transplantation Correlated With the Change in the Monocyte Subset Analysis. Frontiers in Immunology, 2021, 12, 755846.	4.8	2
30	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia, 2021, , .	7.2	3
31	High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2021, 11, 747692.	2.8	3
32	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . Haematologica, 2020, 105, e5-e8.	3.5	34
33	Response to trametinib of histiocytosis with an activating <i>PTPN11</i> mutation. Leukemia and Lymphoma, 2020, 61, 194-197.	1.3	2
34	Lung Involvement in Destombes-Rosai-Dorfman Disease. Chest, 2020, 157, 323-333.	0.8	17
35	Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell, 2020, 37, 123-134.e5.	16.8	186
36	Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study. Open Forum Infectious Diseases, 2020, 7, ofaa394.	0.9	10

#	Article	IF	CITATIONS
37	Multispectral imaging detects gastritis consistently in mouse model and in humans. Scientific Reports, 2020, 10, 20047.	3.3	3
38	Longâ€ŧerm followâ€up of children with risk organâ€negative Langerhans cell histiocytosis after 2â€chlorodeoxyadenosine treatment. British Journal of Haematology, 2020, 191, 825-834.	2.5	14
39	Central nervous system involvement in Erdheim-Chester disease. Neurology, 2020, 95, e2746-e2754.	1.1	22
40	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim–Chester Disease. Cancers, 2020, 12, 3240.	3.7	5
41	Immune phenotyping of Erdheim-Chester disease through mass cytometry highlights decreased proportion of non-classical monocytes and increased proportion of Th17 cells. Annals of the Rheumatic Diseases, 2020, 79, 1522-1524.	0.9	6
42	"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial― Digestive and Liver Disease, 2020, 52, 730-733.	0.9	18
43	Refractory Inflammatory Bowel Disease Associated With Sclerosing Cholangitis, Diabetes Insipidus, and Myeloid Neoplasm: Langerhans Cell Histiocytosis Was Hiding Since the Beginning. Inflammatory Bowel Diseases, 2020, 26, e85-e86.	1.9	3
44	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. Gut, 2020, 69, 681-690.	12.1	79
45	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). Journal of Clinical Oncology, 2020, 38, 1702-1710.	1.6	40
46	Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. , 2020, 8, e000527.		24
47	Sacroiliitis in a patient with Rosai-Dorfman disease: new bone location or overlap with axial spondylarthritis?. Rheumatology, 2020, 59, 2168-2170.	1.9	4
48	Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency. New England Journal of Medicine, 2020, 382, 437-445.	27.0	38
49	Prognostic and predictive value of the Immunoscore in stage III colon cancerÂpatients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Annals of Oncology, 2020, 31, 921-929.	1.2	104
50	Loss of SMARCB1 expression in colon carcinoma. Cancer Biomarkers, 2020, 27, 399-406.	1.7	4
51	Nationwide incidence of sarcomas and tumors of intermediate malignancy in the NETSARC network with central pathology review: Correlation with published clinical research Journal of Clinical Oncology, 2020, 38, 11560-11560.	1.6	0
52	Second primary melanoma in advanced melanoma patients treated with anti-PD-1 monoclonal antibodies Journal of Clinical Oncology, 2020, 38, e22025-e22025.	1.6	0
53	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR) Journal of Clinical Oncology, 2020, 38, 10-10.	1.6	1
54	Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry. Blood, 2020, 136, 15-16.	1.4	15

#	Article	IF	CITATIONS
55	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine, 2019, 46, 94-104.	6.1	24
56	Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digestive and Liver Disease, 2019, 51, 1223-1231.	0.9	49
57	Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. , 2019, 7, 176.		62
58	Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Archives De Pediatrie, 2019, 26, 301-307.	1.0	24
59	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. Cancers, 2019, 11, 1269.	3.7	25
60	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Journal of Clinical Oncology, 2019, 37, 2857-2865.	1.6	132
61	Atteintes ostéoarticulaires au cours des histiocytoses. Revue Du Rhumatisme Monographies, 2019, 86, 120-125.	0.0	0
62	Inherited IL-18BP deficiency in human fulminant viral hepatitis. Journal of Experimental Medicine, 2019, 216, 1777-1790.	8.5	70
63	Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. Haematologica, 2019, 104, e530-e533.	3.5	16
64	Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort. Human Pathology, 2019, 89, 51-61.	2.0	14
65	Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim–Chester Disease,) Tj ETQq1 1 0.784314 rgBT /O Oncology Reports, 2019, 21, 62.	verlock 10 4.0	0 Tf 50 347 48
66	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. British Journal of Cancer, 2019, 120, 697-702.	6.4	19
67	Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. Haematologica, 2019, 104, e502-e505.	3.5	15
68	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122
69	hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers, 2019, 11, 1808.	3.7	23
70	Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation. American Journal of Dermatopathology, 2019, 41, 29-36.	0.6	12
71	Erdheim-Chester Disease: a Concise Review. Current Rheumatology Reports, 2019, 21, 66.	4.7	38
72	Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma. Oncolmmunology, 2019, 8, 1550342.	4.6	36

#	Article	IF	CITATIONS
73	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq1	120378431	l4u2gBT/Ov
74	Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica, 2019, 104, e97-e99.	3.5	27
75	Association of IL-36Î <sup>3</sup> with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunology, Immunotherapy, 2019, 68, 109-120.	4.2	59
76	High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment. Blood, 2019, 134, 2324-2324.	1.4	2
77	Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR) Journal of Clinical Oncology, 2019, 37, 3513-3513.	1.6	8
78	Correlation of BRAF V600E mutation with cardiac involvement assessed by heart imaging in a monocentric series of 205 patients with Erdheim-Chester disease Journal of Clinical Oncology, 2019, 37, 7019-7019.	1.6	2
79	Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR) Journal of Clinical Oncology, 2019, 37, 3519-3519.	1.6	0
80	Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study). Blood, 2019, 134, 2765-2765.	1.4	0
81	Phenotypes and survival in Erdheimâ€Chester disease: Results from a 165â€patient cohort. American Journal of Hematology, 2018, 93, E114-E117.	4.1	94
82	Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. Oncolmmunology, 2018, 7, e1424675.	4.6	66
83	Efficacy of infliximab in the treatment of Erdheim-Chester disease. Annals of the Rheumatic Diseases, 2018, 77, 1387-1390.	0.9	22
84	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood, 2018, 131, 2877-2890.	1.4	335
85	Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncolmmunology, 2018, 7, e1452581.	4.6	115
86	Efficacy of the <scp>MEK</scp> inhibitor cobimetinib for wildâ€ŧype <i><scp>BRAF</scp></i> Erdheimâ€Chester disease. British Journal of Haematology, 2018, 180, 150-153.	2.5	55
87	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With <i>RAS</i> and <i>BRAF</i> Mutational Status. JAMA Oncology, 2018, 4, e173695.	7.1	55
88	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. British Journal of Haematology, 2018, 183, 608-617.	2.5	54
89	Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23. Science Immunology, 2018, 3, .	11.9	152
90	<i>BRAF</i> V600E mutation detected in a case of Rosai-Dorfman disease. Haematologica, 2018, 103, e377-e379.	3.5	45

#	Article	IF	CITATIONS
91	AB1144â€Histology of rosai-dorfman disease in a subset of patients with erdheim-chester disease: a distinct entity mainly driven by map2k1. , 2018, , .		0
92	Histiocytoses. , 2018, , 379-390.		0
93	Hypoalphalipoproteinemia and <i>BRAF</i> <sup>V600E</sup> Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1913-1925.	2.4	15
94	Contribution of genetic amplification by PCR for the diagnosis of <i>Helicobacter pylori</i> infection in patients receiving proton pump inhibitors. United European Gastroenterology Journal, 2018, 6, 1267-1273.	3.8	19
95	<i>CDKN2A</i> Depletion Causes Aneuploidy and Enhances Cell Proliferation in Non-Immortalized Normal Human Cells. Cancer Investigation, 2018, 36, 338-348.	1.3	7
96	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781.	10.7	167
97	Histology of Rosai-Dorfman disease in a subset of patients with Erdheim-Chester disease: A distinct entity mainly driven by MAP2K1 Journal of Clinical Oncology, 2018, 36, e24180-e24180.	1.6	1
98	Improvement of immune response after radiofrequency ablation in colorectal cancer Journal of Clinical Oncology, 2018, 36, 102-102.	1.6	3
99	PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4) Tj ETQq1 1 TPS3622-TPS3622.	0.784314 1.6	rg&T /Overlo
100	Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts Journal of Clinical Oncology, 2018, 36, e21549-e21549.	1.6	1
101	PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease. Blood, 2018, 132, 4380-4380.	1.4	0
102	Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncology, The, 2017, 18, e113-e125.	10.7	154
103	Circulating cellâ€free <i>BRAF</i> <sup>V600E</sup> as a biomarker in children with Langerhans cell histiocytosis. British Journal of Haematology, 2017, 178, 457-467.	2.5	57
104	Reply to "Clinical and therapeutic implications of <i><scp>BRAF</scp></i> mutation heterogeneity in metastatic melanoma―by Mesbah Ardakani etÂal Pigment Cell and Melanoma Research, 2017, 30, 498-500.	3.3	3
105	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood, 2017, 130, 176-180.	1.4	98
106	Adjuvant FOLFOX +/â^' cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients. Annals of Oncology, 2017, 28, 824-830.	1.2	38
107	Neurodegeneration in histiocytoses might start in utero. Lancet Neurology, The, 2017, 16, 953-954.	10.2	2
108	Histiocitosis sistémicas. EMC - Tratado De Medicina, 2017, 21, 1-4.	0.0	0

#	Article	IF	CITATIONS
109	FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood, 2017, 130, 1315-1326.	1.4	87
110	High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis. Blood, 2017, 130, 1007-1013.	1.4	98
111	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	2.8	40
112	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood, 2017, 130, 1377-1380.	1.4	146
113	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer, 2017, 16, 115.	19.2	37
114	Variation of mutant allele frequency in NRAS Q61 mutated melanomas. BMC Dermatology, 2017, 17, 9.	2.1	19
115	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. Oncotarget, 2017, 8, 109818-109835.	1.8	5
116	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort Journal of Clinical Oncology, 2017, 35, 3509-3509.	1.6	24
117	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status Journal of Clinical Oncology, 2017, 35, 3515-3515.	1.6	3
118	<i>BRAF</i> Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology, 2016, 34, 3023-3030.	1.6	233
119	Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30â€year nationwide cohort of 1478 patients under 18Âyears of age. British Journal of Haematology, 2016, 174, 887-898.	2.5	83
120	Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. Acta Oncológica, 2016, 55, 930-932.	1.8	19
121	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	1.4	1,040
122	Increase inNRASmutant allele percentage during metastatic melanoma progression. Experimental Dermatology, 2016, 25, 472-474.	2.9	8
123	A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. Clinical Chemistry, 2016, 62, 1129-1139.	3.2	111
124	Identification of precancerous lesions by multispectral gastroendoscopy. Signal, Image and Video Processing, 2016, 10, 455-462.	2.7	9
125	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. Journal of the American Academy of Dermatology, 2016, 74, 513-520.	1.2	64
126	Prognostic Effect of <i>BRAF</i> and <i>KRAS</i> Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. JAMA Oncology, 2016, 2, 643.	7.1	125

#	Article	IF	CITATIONS
127	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
128	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2016, 18, 205-214.	2.8	23
129	Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses. Blood, 2016, 128, 951-951.	1.4	3
130	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study Journal of Clinical Oncology, 2016, 34, 553-553.	1.6	3
131	Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease Journal of Clinical Oncology, 2016, 34, 7069-7069.	1.6	0
132	Frequent allelic imbalance in <i>NRAS</i> mutant melanomas Journal of Clinical Oncology, 2016, 34, 9578-9578.	1.6	0
133	Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib Journal of Clinical Oncology, 2016, 34, e19074-e19074.	1.6	0
134	Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood, 2015, 126, 1163-1171.	1.4	69
135	Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. Blood, 2015, 125, 2448-2449.	1.4	28
136	Complete remission of critical neurohistiocytosis by vemurafenib. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e78.	6.0	38
137	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With <i>BRAF<sup>V600E</sup></i> -Mutated Erdheim-Chester Disease. Journal of Clinical Oncology, 2015, 33, 411-418.	1.6	238
138	The histiocytosis Erdheim–Chester disease is an inflammatory myeloid neoplasm. Expert Review of Clinical Immunology, 2015, 11, 1033-1042.	3.0	38
139	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. Journal of the American Academy of Dermatology, 2015, 73, e29-e30.	1.2	22
140	Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncology, 2015, 1, 836.	7.1	92
141	Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. Journal of the American Academy of Dermatology, 2015, 72, 786-793.	1.2	37
142	Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma. Clinical Cancer Research, 2015, 21, 1215-1224.	7.0	63
143	Variations of BRAF mutant allele percentage in melanomas. BMC Cancer, 2015, 15, 497.	2.6	36
144	Clinical Relevance of <i>KRAS</i> -Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy. Clinical Cancer Research, 2015, 21, 1087-1097.	7.0	137

#	Article	IF	CITATIONS
145	Prognostic value of <i>BRAF<sup>V600</sup></i> mutations in American Joint Committee on Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort prospective cohort Journal of Clinical Oncology, 2015, 33, 9037-9037.	1.6	1
146	Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. PLoS ONE, 2015, 10, e0120232.	2.5	24
147	Langerhans cell histiocytosis in children: Correlation of <i>BRAF</i> status with clinical characteristic Journal of Clinical Oncology, 2015, 33, 10003-10003.	1.6	0
148	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. Journal of Cancer, 2014, 5, 425-432.	2.5	30
149	<i>BRAF</i> <sup>V600E</sup> Mutation in a Histiocytic Sarcoma Arising From Hairy Cell Leukemia. Journal of Clinical Oncology, 2014, 32, e117-e121.	1.6	47
150	Detection of <i>BRAF</i> p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives of Pathology and Laboratory Medicine, 2014, 138, 71-75.	2.5	57
151	Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology, 2014, 83, 1294-1296.	1.1	29
152	Dramatic response of a <i>BRAF</i> V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology, 2014, 83, 1478-1480.	1.1	70
153	Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors. Molecular Cancer, 2014, 13, 246.	19.2	12
154	Erdheim–Chester Disease. Current Rheumatology Reports, 2014, 16, 412.	4.7	110
155	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 862-873.	10.7	239
156	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 2014, 124, 3016-3019.	1.4	197
157	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood, 2014, 124, 1119-1126.	1.4	208
158	Prognostic value of <i> KRAS </i> exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial Journal of Clinical Oncology, 2014, 32, 3549-3549.	1.6	0
159	Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. European Journal of Cancer, 2013, 49, 2531-2541.	2.8	41
160	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472.	2.6	11
161	Effects of endoplasmic reticulum stressors on maturation and signaling ofÂhemizygous and heterozygous wildâ€ŧype and mutant forms of KIT. Molecular Oncology, 2013, 7, 323-333.	4.6	9
162	Detection of BRAF p.V600E Mutations in Melanomas. Journal of Molecular Diagnostics, 2013, 15, 94-100.	2.8	144

#	Article	IF	CITATIONS
163	<i>BRAF</i> Mutations in Erdheim-Chester Disease. Journal of Clinical Oncology, 2013, 31, 398-398.	1.6	65
164	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 2013, 121, 1495-1500.	1.4	479
165	Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience. PLoS ONE, 2013, 8, e68945.	2.5	23
166	Impact of mutational status and other prognostic factors on survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group Journal of Clinical Oncology, 2013, 31, 10548-10548.	1.6	2
167	Gene Expression Patterns of Hemizygous and Heterozygous KIT Mutations Suggest Distinct Oncogenic Pathways: A Study in NIH3T3 Cell Lines and GIST Samples. PLoS ONE, 2013, 8, e61103.	2.5	9
168	Relationship of the topography of KIT exon 11 alterations and predictive value for PFS in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial Journal of Clinical Oncology, 2013, 31, 10542-10542.	1.6	0
169	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 2012, 120, 2700-2703.	1.4	589
170	Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes. Annals of Surgical Oncology, 2012, 19, 4314-4321.	1.5	91
171	Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. Diagnostic Pathology, 2012, 7, 156.	2.0	28
172	Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. Gastroenterology, 2012, 143, 664-674.e6.	1.3	218
173	A Mild Form of SLC29A3 Disorder: A Frameshift Deletion Leads to the Paradoxical Translation of an Otherwise Noncoding mRNA Splice Variant. PLoS ONE, 2012, 7, e29708.	2.5	50
174	B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease. PLoS ONE, 2012, 7, e33891.	2.5	132
175	Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Experimental and Molecular Pathology, 2012, 92, 275-280.	2.1	106
176	miRNA expression as a predictor of survival in patients with metastatic colorectal cancer treated with EGFR inhibitors Journal of Clinical Oncology, 2012, 30, e14059-e14059.	1.6	0
177	Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes Journal of Clinical Oncology, 2012, 30, 8540-8540.	1.6	1
178	Langerhans' cell histiocytosis of the liver in adults. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 475-481.	1.5	46
179	Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. Clinical Cancer Research, 2011, 17, 7470-7478.	7.0	76
180	Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors. The Application of Clinical Genetics, 2010, 3, 85.	3.0	10

#	Article	IF	CITATIONS
181	GIST with homozygous KIT exon 11 mutations. Laboratory Investigation, 2008, 88, 456-457.	3.7	13
182	<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Journal of Clinical Oncology, 2008, 26, 374-379.	1.6	1,398
183	Consensus meeting for the management of gastrointestinal stromal tumorsâ€ <sup>-</sup> Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Annals of Oncology, 2005, 16, 566-578.	1.2	628
184	Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clinical Gastroenterology and Hepatology, 2004, 2, 597-605.	4.4	82
185	High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1688, 250-256.	3.8	29
186	Langerhans cell histiocytosis in adultsReport from the International Registry of the Histiocyte Society. European Journal of Cancer, 2003, 39, 2341-2348.	2.8	450
187	Length Analysis of Polymerase Chain Reaction Products: A Sensitive and Reliable Technique for the Detection of Mutations in KIT Exon 11 in Gastrointestinal Stromal Tumors. Diagnostic Molecular Pathology, 2002, 11, 107-112.	2.1	28
188	Definitive Diagnosis with the Use of Monoclonal Antibody O10 on Routinely Paraffin-embedded Samples. American Journal of Surgical Pathology, 1995, 19, 636-641.	3.7	148